Your browser doesn't support javascript.
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis.
Giugliano, Federica; Zucali, Paolo A; Galli, Giulia; Ballatore, Zelmira; Corti, Chiara; Aliaga, Pamela T; Uliano, Jacopo; Vivanet, Grazia; Curigliano, Giuseppe; Conforti, Fabio; Queirolo, Paola; Berardi, Rossana; Manglaviti, Sara; Apollonio, Giulia; Perrino, Matteo; Borea, Federica; D'Antonio, Federica; Garassino, Marina C; De Pas, Tommaso.
  • Giugliano F; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Zucali PA; Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.
  • Galli G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Ballatore Z; Department of Medical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti di Ancona, Italy.
  • Corti C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Aliaga PT; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
  • Uliano J; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Vivanet G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Conforti F; Division of Medical Oncology for Melanoma, Sarcoma & Rare Tumours, European Institute of Oncology, IRCCS, Milan, Italy.
  • Queirolo P; Division of Medical Oncology for Melanoma, Sarcoma & Rare Tumours, European Institute of Oncology, IRCCS, Milan, Italy.
  • Berardi R; Department of Medical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti di Ancona, Italy.
  • Manglaviti S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Apollonio G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Perrino M; Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
  • Borea F; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.
  • D'Antonio F; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.
  • Garassino MC; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Thoracic Oncology Program, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
  • De Pas T; Division of Medical Oncology for Melanoma, Sarcoma & Rare Tumours, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: Tommaso.depas@ieo.it.
Eur J Cancer ; 166: 202-207, 2022 05.
Article in English | MEDLINE | ID: covidwho-1706358
ABSTRACT

BACKGROUND:

International guidelines recommend severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine for patients with cancer. A substantial risk of developing vaccine-related autoimmune toxicities could be hypothesised for patients with thymic epithelial tumours (TETs) due to their high risk of autoimmune disorders (ADs). Moreover, a cross-reaction between SARS-CoV-2 spike protein antibodies and various tissue proteins has been shown, and antibodies against nucleoproteins showed overlaps in the autoimmune cross-reaction with antibodies to spike protein. Due to the rarity of TETs, no data addressing this hypothesis are available.

METHODS:

Patients with TETs who received SARS-CoV-2 vaccine, treated in 4 referral centres of the Italian Collaborative Group for ThYmic MalignanciEs (TYME) network between February 2021 and September 2021, were interviewed through a standardised 15-items questionnaire in order to describe the safety of SARS-CoV-2 vaccine in patients affected by TETs.

RESULTS:

Data from 245 doses of vaccine administered to 126 patients (41 = thymic carcinoma, 85 = thymoma; 38 with AD, of which 26 with active AD) were collected. Nine patients had a previous COVID-19-positive swab. No cases of AD reactivation or worsening of a pre-existing AD were seen in the study population. A new diagnosis of myasthenia gravis likely unrelated to the vaccine was made in two patients after the vaccination. Sixty-four patients (51%) experienced a total of 103 adverse events, all G1/G2, most commonly fatigue, new or worsening muscle pain and chills. None AE required patients' hospitalisation.

CONCLUSIONS:

SARS-CoV-2 mRNA vaccines appear to be safe in patients with TET, even in case of active or pre-existing AD.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Thymus Neoplasms / Neoplasms, Glandular and Epithelial / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Eur J Cancer Year: 2022 Document Type: Article Affiliation country: J.ejca.2022.02.011

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Thymus Neoplasms / Neoplasms, Glandular and Epithelial / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Eur J Cancer Year: 2022 Document Type: Article Affiliation country: J.ejca.2022.02.011